146,332 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Purchased by Foresite Capital Management VI LLC

Foresite Capital Management VI LLC purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 146,332 shares of the company’s stock, valued at approximately $5,887,000. Kymera Therapeutics accounts for 2.6% of Foresite Capital Management VI LLC’s investment portfolio, making the stock its 12th biggest position.

Several other large investors have also modified their holdings of KYMR. Wellington Management Group LLP raised its holdings in shares of Kymera Therapeutics by 14.9% in the 4th quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after purchasing an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 3.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company’s stock valued at $276,395,000 after purchasing an additional 224,859 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 2.8% in the 4th quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company’s stock valued at $196,617,000 after purchasing an additional 133,546 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Kymera Therapeutics by 212.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after purchasing an additional 95,547 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on KYMR. HC Wainwright boosted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Citigroup initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price objective for the company. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Insider Transactions at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the transaction, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,659 shares of company stock worth $324,567 in the last ninety days. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Trading Down 0.9 %

NASDAQ:KYMR opened at $33.26 on Monday. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The stock has a 50 day moving average of $29.89 and a two-hundred day moving average of $38.54. The firm has a market cap of $2.16 billion, a P/E ratio of -14.21 and a beta of 2.22.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.